|Bid||0.00 x 800|
|Ask||0.00 x 800|
|Day's Range||175.04 - 178.42|
|52 Week Range||136.50 - 183.39|
|PE Ratio (TTM)||109.65|
|Earnings Date||Oct 23, 2018 - Oct 29, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||196.52|
Vertex Pharmaceuticals is the IBD Stock Of The Day as shares near a breakout amid a flurry of recent news surrounding its cystic fibrosis treatments.
Vertex Pharmaceuticals (VRTX) seems well-positioned for future earnings growth and it is seeing rising earnings estimates as well, coupled with a solid Zacks Rank.
Novo Nordisk A/S (NVO) acquires Ziylo Ltd. to speed up the development of glucose responsive insulins in a deal that could exceed $800 million.
Zacks.com highlights: Illumina, Vertex Pharmaceuticals, Surmodics and McDermott International
A company with a favorable efficiency level is expected to provide stellar returns as it is believed to be positively correlated with price performance.
Vertex Pharmaceuticals (VRTX) sees solid earnings estimate revisions and looks poised to shock the market, and yet seems overlooked by the investors.
How Is Vertex Pharmaceuticals Positioned in August? In its Q2 2018 earnings conference call, Vertex Pharmaceuticals (VRTX) reiterated its projection for non-GAAP combined selling, general, and administrative (or SG&A) and research and development (or R&D) expenses to come in in the range of $1.5 billion and $1.55 billion for fiscal 2018. In Q2 2018, the company reported non-GAAP combined R&D and SG&A expenses close to $388 million.
Vertex today announced the recipients of the annual Vertex Science Leaders Scholarship, a four-year, full-ride scholarship to pursue an education in science, technology, engineering, art or math (STEAM) at any University of Massachusetts campus.
In its Q2 2018 earnings conference call, Vertex Pharmaceuticals (VRTX) updated its revenue guidance for fiscal 2018 from the previously projected range of $2.65 billion–$2.8 billion to $2.9 billion–$3.0 billion. The midpoint of this guidance range would imply a 36% year-over-year (or YoY) rise in revenues in fiscal 2018. This expectation has mainly been driven by the solid adoption of Symdeko since its launch in US markets. The company has not assumed the impact of securing new reimbursement for its CF drugs in markets outside the US in its fiscal 2018 revenue guidance.
Vertex Pharmaceuticals Incorporated (VRTX) today announced the U.S. Food and Drug Administration (FDA) approved KALYDECO® (ivacaftor) to include use in children with cystic fibrosis (CF) ages 12 to
Shares of Bayer (BAYRY) crash as its newly acquired company Monsanto was fined $289 million over allegations that its weedkiller caused cancer.
NEW YORK, Aug. 10, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Immunomedics, ...
In the second quarter, Exelixis’s (EXEL) cabozantinib franchise generated revenues of $145.8 million, which was a ~66% YoY (year-over-year) growth. Exelixis’s net product revenues grew 9% sequentially in the second quarter. In the second quarter, Ipsen, Exelixis’s partner, generated cumulative revenues of $150 million from sales of cabozantinib.
Crispr's stock has started to lose momentum after blasting higher earlier this year. Is the market correcting a prior mistake, or is this dip a buying opportunity?
Infinity (INFI) posts narrower-than-expected loss in the second quarter of 2018 and provides update on pipeline candidate, IPI 549.
The last leg of Q2 earnings in the biotech sector saw Regeneron firing all cylinders. The company also collaborated with bluebird bio, which impressed investors.
Vertex Pharmaceuticals Incorporated (VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved ORKAMBI® (lumacaftor/ivacaftor) to include use in children ages 2 through 5 years with cystic fibrosis (CF) who have two copies of the F508del-CFTR mutation, making it the first medicine approved to treat the underlying cause of CF in this population. ORKAMBI oral granules are available in two dosage strengths (lumacaftor 100mg/ivacaftor 125mg and lumacaftor 150mg/ivacaftor 188mg) for weight-based dosing. ORKAMBI oral granules should be available for fulfillment within 2 to 4 weeks.
Stifel updated its outlook on the biotech sector, and sees reason to be bullish on several big names. While biotech has had its ups and downs, in general this has been a good year to be in the sector: The iShares Nasdaq Biotechnology ETF (IBB) and the SPDR S&P Biotech ETF (XBI) have risen 10.7% and 12.8%, respectively, since the start of 2018, above the broader market and even the gain seen by the increasing popular health-care sector itself, as the Health Care Select Sector SPDR ETF (XLV) is up 8.8% since the start of the year. While smaller biotechs have benefited more from the moves, there are still some bigger companies that warrant attention, argues Stifel's Paul Matteis. Stifel transferred and initiated coverage on a number of biotech stocks, today, with Buy ratings on Vertex Pharmaceuticals (VRTX), BioMarin Pharmaceuticals (BMRN), Biogen (BIIB), Alnylam Pharmaceuticals (ANLY), Sage Therapeutics (SAGE), Neurocrine Biosciences (NBIX), Wave Life Sciences (WVE), and Alder BioPharmaceuticals (ALDR).
Wall Street analysts estimate Sarepta will report a net loss of $0.89 per share on revenues of $71.6 million in Q2 2018, which is more than a 100% YoY increase in revenues as compared to $35.0 million during the second quarter of 2017. Wall Street analyst estimates suggest the stock has the potential to return ~51.4% over the next 12 months. As of August 6, 19 analysts were tracking Sarepta Therapeutics stock.
Impressive second-quarter results by most biotech bigwigs were the key highlights of the week. Most companies upped their guidance.